SCHEMBL4017792

SCHEMBL4017792

COc1cc(N2CCN(C(C=O)n3nc(-c4cccc(F)c4)c(Cl)c3C(F)(F)F)CC2)ccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 19/20 0.45
CYP2C19 P33261 1/20 0.41
KCNH2 Q12809 1/20 0.41
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4019936 0.88 CCR1 (0.47) CCR1CYP2C19KCNH2
SCHEMBL4020840 0.87 CCR1 (0.46) CCR1CYP2C19KCNH2
SCHEMBL27642393 0.86 CCR1 (0.48) CCR1CYP2C19KCNH2
SCHEMBL4016751 0.85 CCR1 (0.53) CCR1CYP2C19KCNH2
SCHEMBL4556935 0.85 CCR1 (0.43) CCR1CYP2C19KCNH2
SCHEMBL4013693 0.84 CCR1 (0.45) CCR1CYP2C19KCNH2
SCHEMBL4019530 0.84 CCR1 (0.47) CCR1CYP2C19KCNH2
SCHEMBL3854887 0.82 CCR1 (0.52) CCR1CYP2C19KCNH2
SCHEMBL27642390 0.81 CCR1 (0.52) CCR1CYP2C19KCNH2
SCHEMBL4021532 0.81 CCR1 (0.43) CCR1CYP2C19KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1691810-A4 SUBSTITUTED PIPERAZINES CHEMOCENTRYX INC (US) 2009-07-01 EP disclosed
EP-1691810-A1 SUBSTITUTED PIPERAZINES ChemoCentryx Inc (US) 2006-08-23 EP disclosed
WO-2005056015-A1 SUBSTITUTED PIPERAZINES CHEMOCENTRYX, INC. (US) 2005-06-23 WO disclosed
EP-1531822-A1 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS Chemocentryx, Inc. (US) 2005-05-25 EP disclosed
WO-2003105853-A1 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS CHEMOCENTRYX, INC. (US) 2003-12-24 WO disclosed